ATE501760T1 - E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen - Google Patents

E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen

Info

Publication number
ATE501760T1
ATE501760T1 AT07019438T AT07019438T ATE501760T1 AT E501760 T1 ATE501760 T1 AT E501760T1 AT 07019438 T AT07019438 T AT 07019438T AT 07019438 T AT07019438 T AT 07019438T AT E501760 T1 ATE501760 T1 AT E501760T1
Authority
AT
Austria
Prior art keywords
versus
host
treatment
allograft rejection
graft diseases
Prior art date
Application number
AT07019438T
Other languages
English (en)
Inventor
Daniel P Rossignol
Melvyn Lynn
William D Kerns
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE501760T1 publication Critical patent/ATE501760T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT07019438T 1999-01-14 2000-01-14 E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen ATE501760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11620299P 1999-01-14 1999-01-14

Publications (1)

Publication Number Publication Date
ATE501760T1 true ATE501760T1 (de) 2011-04-15

Family

ID=22365882

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00904375T ATE375798T1 (de) 1999-01-14 2000-01-14 Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion
AT07019438T ATE501760T1 (de) 1999-01-14 2000-01-14 E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00904375T ATE375798T1 (de) 1999-01-14 2000-01-14 Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion

Country Status (11)

Country Link
EP (3) EP2298326A3 (de)
JP (1) JP2002534471A (de)
AT (2) ATE375798T1 (de)
AU (1) AU2614400A (de)
CA (1) CA2359478A1 (de)
CY (1) CY1108039T1 (de)
DE (2) DE60045750D1 (de)
DK (1) DK1158990T3 (de)
ES (1) ES2291188T3 (de)
PT (1) PT1158990E (de)
WO (1) WO2000041703A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105033A1 (en) 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20020042379A1 (en) * 2000-06-09 2002-04-11 Daniel Rossignol Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20040254128A1 (en) * 2001-08-10 2004-12-16 Seiichi Kobayashi Treatment and prevention of heat shock protein-associated diseases and conditions
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
CA2970529C (en) 2014-12-12 2019-07-02 The Feinstein Institute For Medical Research Treatment of hmgb1-mediated inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Also Published As

Publication number Publication date
WO2000041703A1 (en) 2000-07-20
EP1867336A2 (de) 2007-12-19
EP2298326A3 (de) 2011-04-27
DK1158990T3 (da) 2008-01-28
CY1108039T1 (el) 2013-09-04
EP1158990A1 (de) 2001-12-05
PT1158990E (pt) 2007-12-21
DE60036790D1 (de) 2007-11-29
JP2002534471A (ja) 2002-10-15
DE60045750D1 (de) 2011-04-28
AU2614400A (en) 2000-08-01
EP2298326A2 (de) 2011-03-23
DE60036790T2 (de) 2008-07-24
ATE375798T1 (de) 2007-11-15
EP1867336B1 (de) 2011-03-16
EP1158990A4 (de) 2003-08-13
EP1867336A3 (de) 2008-04-23
CA2359478A1 (en) 2000-07-20
ES2291188T3 (es) 2008-03-01
EP1158990B1 (de) 2007-10-17

Similar Documents

Publication Publication Date Title
DE69910045D1 (de) Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
FR12C0004I1 (de)
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE69924870D1 (de) Peptidvektoren von stoffen die durch die blut-hirn-scranke dringen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
ATE477816T1 (de) Botulinum toxin zur behandlung von akuten verletzungen der skelettmuskeln
HUP9700368A2 (hu) II-típusú diabetes mellitus kezelése amilin agonistákkal
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
ATE501760T1 (de) E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
EA199800821A1 (ru) Способ лечения аутизма
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ES2082212T3 (es) Nuevos inhibidores de alfa-glucosidasa.
EA199800822A1 (ru) Способ лечения избыточной агрессии
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE59405845D1 (de) Verwendung von 2-Methylamino-2-phenylcyclohexanon zur Behandlung von Infektionen und zur Immunmodulation
DE69103294D1 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties